External pacemaker systems and methods deliver pacing waveforms that minimize hydrolysis of the electrode gel. compensating pulses are interleaved with the pacing pulses, with a polarity and duration that balance the net charge at the electrode locations. The compensating pulses are preferably rectangular for continuous pacing, and decay individually for on-demand pacing.
|
2. A system for transcutaneous cardiac pacing comprising:
electrodes for transcutaneous pacing;
means for applying through the electrodes a series of cardiac pacing pulses having a first polarity; and
means for applying through the electrodes a series of compensating pulses interleaved with the cardiac pacing pulses, the compensating pulses having a second polarity opposite to the first polarity so that an amount of charge of the second polarity substantially or exactly equal to a charge of the first polarity is applied by the electrodes and configured to:
start approximately immediately at an end of a first cardiac pacing pulse and last up to an onset of a second cardiac pacing pulses that succeeds the first cardiac pacing pulse.
1. A transcutaneous cardiac pacing method comprising:
applying pacing electrodes to a patient for transcutaneous pacing;
applying through the electrodes a series of cardiac pacing pulses; and
applying through the electrodes a series of compensating pulses interleaved with the cardiac pacing pulses, the compensating pulses having a polarity opposite to a polarity of the cardiac pacing pulses to at least substantially compensate for a charge of the cardiac pacing pulses and configured to:
start approximately immediately at an end of a first cardiac pacing pulse and last up to an onset of a second cardiac pacing pulse that succeeds the first cardiac pacing pulse,
the pacing pulses and compensating pulses being configured so that a net current applied to a patient is substantially or exactly zero.
|
This application is a division of U.S. patent application Ser. No. 10/396,023 entitled “BALANCED CHARGE WAVEFORM FOR TRANSCUTANEOUS PACING” filed Mar. 24, 2003, and issued as U.S. Pat. No. 8,027,721 on Sep. 27, 2011.
The present invention relates generally to medical pacemaker systems, and more particularly to devices and methods that generate pacing waveforms for minimizing patient skin burns during long-term transcutaneous defibrillation.
Systems are made for administering to patients pacing pulses externally. Advantageously, external defibrillators may also administer such external pacing. A common electrode used to connect a heart pacer to a patient incorporates an electrically conductive, impedance-decreasing gel disposed between a flexible conductive plate and the patient's skin. The gel ensures good electrical contact between the patient and the conductive plate, and adheres the electrode to the patient's skin. During pacing, pulses are generated by the heart pacer and applied through the electrodes and into the patient. Typical pacing equipment will commonly deliver a pacing pulse having an amplitude of up to 300 volts, and a maximum current of about 0.2 amps. Such a pacing pulse may be applied to a patient up to 170 times a minute, for periods as long as 24 hours.
Application of pacing waveform 10 generates an excess of positive charge flowing through the electrodes. The excess charge causes hydrolysis of the electrode gel, producing hydrogen and oxygen between the electrode and the patient's skin. During long-term transcutaneous pacing, the generation of hydrogen and oxygen causes the electrode impedance to increase and the electrode pH to change.
A problem arises when such transcutaneous pacing is long-term. The changes of an electrode's impedance and pH are dramatic. The hydrogen and oxygen gas, which tend to accumulate between the patient's skin and the flexible conductive plate, and produces two primary undesirable effects. First, the accumulation of the gases generally decreases the conductivity between the electrode and the patient. As the impedance of the electrodes increases, the pacer is forced to compensate by applying a higher voltage to produce a suitable pacing current. Generally, the impedance of the electrodes may reach such a high value that the pacer is unable to generate a sufficient voltage to apply a pacing pulse. At this point, many pacers may stop pacing, and instead generate a “leads off” alarm, on the erroneous determination that the high resistance is caused by one of the electrodes having fallen off the patient.
Second, the gas has a tendency to accumulate in pockets, causing the current density in areas of the electrode to increase. The bubbles tend to insulate the conductive plate from the patient, reducing the surface area of the electrode in contact with the patient. If the density of current flow increases in the areas remaining in contact with the patient, patient discomfort may result. If the current density increases even further, burning of the patient's skin may result. The increasing current density problem is exacerbated with electrodes designed for pediatric use. Pediatric electrodes tend to be smaller and have a smaller conductive surface, yet have current flows comparable to electrodes used for adults.
As hydrolysis occurs during long-term pacing, the pH of the electrode also has a tendency to change. The formation of hydrogen and oxygen bubbles within the electrode cause the gel of one electrode to become more acidic, and the gel of the other electrode to become more basic. For children or patients with sensitive skin, the change in electrode pH can become highly irritating to the dermic layer.
One approach to minimizing the buildup of hydrogen and oxygen gas has been to construct the electrodes in a manner that minimizes the amount of gas that may accumulate. For example, U.S. Pat. No. 5,456,710 entitled ‘VENTED ELECTRODE” discloses an electrode construction that allows hydrogen and oxygen buildup within an electrode to pass through a gas-permeable layer and escape from beneath the electrode. The gas generated by hydrolysis can therefore vent to the environment before accumulating and causing the impedance or pH of the electrode to change.
While the accumulation of hydrogen and oxygen in the electrodes may be prevented by appropriately constructing the electrodes, such a solution is only applicable in limited circumstances. The majority of pacing performed today uses traditional, non-vented conducting pads. For those situations where non-vented electrodes are being used, it would be advantageous to find an alternative technique to minimize the hydrolysis of the electrode gel such that the impedance and pH of the electrodes would remain relatively constant over an extended period of time.
The invention overcomes the problem of the prior art. The invention provides external pacemaker systems and methods that deliver pacing waveforms that alleviate the problem of the prior art, by minimizing the hydrolysis of the electrode gel, and thus prevent the resulting harmful effects.
The invention delivers a series of pacing pulses to provide pacing to the patient. In addition, the invention applies a series of compensating pulses interleaved with the pacing pulses. The compensating pulses having a polarity opposite to a polarity of the pacing pulses, to substantially compensate for a long-term charge of the pacing pulses.
Accordingly, the invention generates pacing waveforms that maintain a balanced charge in the electrodes. This minimizes the hydrolysis of the electrode gel during long-term transcutaneous pacing. The invention thus allows long-term transcutaneous pacing without fear that the pacing will be stopped due to excessive electrode impedance. In addition, the invention allows the devices, methods, and waveforms of the invention to be applied using conventional electrodes.
The foregoing and other aspects and attendant advantages of the invention will become more readily appreciated as the same becomes better understood by reference to the following detailed description, when taken in conjunction with the accompanying drawings, wherein:
The following detailed description is merely exemplary in nature and is not intended to limit the invention or the application and uses of the invention. Furthermore, there is no intention to be bound by any expressed or implied theory presented in the preceding technical field, background, brief summary or the following detailed description. As has been mentioned, the invention provides external pacemaker systems and methods that deliver charge-balanced pacing waveforms that alleviate the problems arising from the hydrolysis of the electrode gel. The invention is now described in more detail.
Referring to
As shown in
Referring to
Referring back to
During on-demand pacing, however, a pacing pulse for stimulating that patient is generated only when an absence of a patient's heartbeat is detected. Several stimulating pulses may therefore be regularly applied for a period of time, followed by a period when no stimulating pulses are applied. As such, the balance charge waveform 20 shown in
Other waveforms according to the invention are now described, that are better suited for on-demand pacing. In those, a current of the compensating pulses has a waveform of decay from an initially high value. The decay ends in a zero value. In some embodiments, as is preferred, the decay completes to bring the pulse to zero before the next pulse is applied, which ensures that the charge of the waveform remains balanced. In other embodiments the decay may be interrupted by the next pacing pulse, but is brought to zero if no other pacing pulse is applied. These other embodiments are not preferred, however, because they would not result in an exactly balanced charge.
Referring to
Referring to
Those skilled in the art will recognize that there are many different forms that the trailing edge of the compensating pulse can take. The two representative forms disclosed herein are advantageous, in that they are easily generated using capacitors as decay elements. Those skilled in the art will recognize, however, that by digitizing the waveforms, the trailing edge can take a variety of different shapes. As disclosed by the method herein, however, two features of the trailing edge are preferably embodied: (1) the amplitude of the compensating current pulse should decay to nearly 0; and (2) the decay is relatively continuous, with few rapid changes in the amplitude, else artifacts might be caused in a monitored heart waveform.
While the preferred embodiment of the invention has been illustrated and described, it will be appreciated that various changes can be made therein without departing from the spirit and scope of the invention. For example, even approximate balancing that only substantially (but not exactly) compensates is within the invention, and will result in substantially alleviating the prior art problems.
Patent | Priority | Assignee | Title |
Patent | Priority | Assignee | Title |
4821723, | Feb 27 1987 | INTERMEDICS, INC , A TX CORP | Biphasic waveforms for defibrillation |
5083562, | Jan 19 1988 | Pacesetter, Inc | Method and apparatus for applying asymmetric biphasic truncated exponential countershocks |
5205284, | Jun 12 1990 | ZOLL Medical Corporation | Method and apparatus for transcutaneous electrical cardiac pacing with background stimulation |
5456710, | Jun 30 1994 | PHYSIO-CONTROL, INC | Vented electrode |
5601608, | Feb 02 1995 | Pacesetter, Inc.; Pacesetter, Inc | Methods and apparatus for applying charge-balanced antiarrhythmia shocks |
5782882, | Nov 30 1995 | Koninklijke Philips Electronics N V | System and method for administering transcutaneous cardiac pacing with transcutaneous electrical nerve stimulation |
5871506, | Aug 19 1996 | MR3 MEDICAL, LLC | Augmentation of electrical conduction and contractility by biphasic cardiac pacing |
5964787, | Apr 17 1998 | Vitatron Medical B.V. | Stimulus system with controllable switched capacitor output stage |
6067470, | Mar 05 1998 | MR3 MEDICAL, LLC | System and method for multiple site biphasic stimulation to revert ventricular arrhythmias |
6136019, | Aug 08 1996 | MR3 MEDICAL, LLC | Augmentation of electrical conduction and contractility by biphasic cardiac pacing administered via the cardiac blood pool |
6141586, | Aug 08 1996 | MR3 MEDICAL, LLC | Method and apparatus to allow cyclic pacing at an average rate just above the intrinsic heart rate so as to maximize inotropic pacing effects at minimal heart rates |
6141587, | Jan 16 1998 | MR3 MEDICAL, LLC | Augmentation of muscle contractility by biphasic stimulation |
6178351, | Aug 19 1996 | MR3 MEDICAL, LLC | Atrial sensing and multiple site stimulation as intervention means for atrial fibrillation |
6256534, | Aug 11 1998 | ELA MEDICAL, S A | Implantable defibrillator with countershock synchronized to P-wave |
6295470, | Aug 19 1996 | MR3 MEDICAL, LLC | Antitachycardial pacing |
6332096, | Feb 16 2000 | MR3 MEDICAL, LLC | Augmentation of electrical conduction and contractility by biphasic cardiac pacing |
6337995, | Aug 19 1996 | MR3 MEDICAL, LLC | Atrial sensing and multiple site stimulation as intervention for atrial fibrillation |
6341235, | Aug 19 1996 | MR3 MEDICAL, LLC | Augmentation of electrical conduction and contractility by biphasic cardiac pacing administered via the cardiac blood pool |
6343232, | Aug 19 1966 | MR3 MEDICAL, LLC | Augmentation of muscle contractility by biphasic stimulation |
6411845, | Mar 04 1999 | MR3 MEDICAL, LLC | System for multiple site biphasic stimulation to revert ventricular arrhythmias |
6411847, | Aug 19 1996 | MR3 MEDICAL, LLC | Apparatus for applying cyclic pacing at an average rate just above the intrinsic heart rate |
6487448, | Oct 13 1998 | PHYSIO-CONTROL, INC | Method and apparatus for converting a monophasic defibrillator to a biphasic defibrillator |
6505079, | Sep 13 2000 | Foster Bio Technology Corp.; FOSTER BIO TECHNOLOGY CORP | Electrical stimulation of tissue for therapeutic and diagnostic purposes |
6697670, | Aug 17 2001 | AngioDynamics, Inc | Apparatus and method for reducing subcutaneous fat deposits by electroporation with improved comfort of patients |
6751501, | Jul 17 1997 | Codes of Life, LLC | Method and apparatus for myocardial control |
6980856, | Oct 13 1998 | PHYSIO-CONTROL, INC | Circuit for performing external pacing and biphasic defibrillation |
RE38119, | Jan 23 1989 | MIROWSKI FAMILY VENTURES, LLC | Method and apparatus for treating hemodynamic disfunction |
Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
Mar 21 2003 | SULLIVAN, JOSEPH L | Medtronic Physio-Control Manufacturing Corporation | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 028012 | /0188 | |
Sep 02 2011 | Physio-Control, Inc. | (assignment on the face of the patent) | / | |||
Oct 03 2011 | Medtronic Physio-Control Manufacturing Corporation | PHYSIO-CONTROL, INC | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 028012 | /0248 | |
Jan 30 2012 | PHYSIO-CONTROL, INC | CITIBANK, N A , AS COLLATERAL AGENT | SECURITY AGREEMENT | 027763 | /0881 | |
Jan 30 2012 | PHYSIO-CONTROL, INC | BANK OF NEW YORK MELLON TRUST COMPANY, N A , AS *COLLATERAL TRUSTEE, THE | SECURITY AGREEMENT | 027765 | /0861 | |
Jun 05 2015 | PHYSIO-CONTROL INTERNATIONAL, INC | CITIBANK, N A , AS COLLATERAL AGENT | SECOND LIEN SECURITY AGREEMENT | 037559 | /0601 | |
Jun 05 2015 | PHYSIO-CONTROL, INC | CITIBANK, N A , AS COLLATERAL AGENT | SECOND LIEN SECURITY AGREEMENT | 037559 | /0601 | |
Jun 05 2015 | PHYSIO-CONTROL INTERNATIONAL, INC | CITIBANK, N A , AS COLLATERAL AGENT | FIRST LIEN SECURITY AGREEMENT | 037532 | /0828 | |
Jun 05 2015 | PHYSIO-CONTROL, INC | CITIBANK, N A , AS COLLATERAL AGENT | FIRST LIEN SECURITY AGREEMENT | 037532 | /0828 | |
Jun 05 2015 | THE BANK OF NEW YORK MELLON TRUST COMPANY, N A | PHYSIO-CONTROL, INC | RELEASE BY SECURED PARTY SEE DOCUMENT FOR DETAILS | 037519 | /0240 | |
Apr 05 2016 | CITIBANK, N A | PHYSIO-CONTROL INTERNATIONAL, INC | RELEASE BY SECURED PARTY SEE DOCUMENT FOR DETAILS | 038378 | /0028 | |
Apr 05 2016 | CITIBANK, N A | PHYSIO-CONTROL, INC | RELEASE BY SECURED PARTY SEE DOCUMENT FOR DETAILS | 038378 | /0028 |
Date | Maintenance Fee Events |
Jul 30 2020 | M1551: Payment of Maintenance Fee, 4th Year, Large Entity. |
Oct 07 2024 | REM: Maintenance Fee Reminder Mailed. |
Date | Maintenance Schedule |
Feb 14 2020 | 4 years fee payment window open |
Aug 14 2020 | 6 months grace period start (w surcharge) |
Feb 14 2021 | patent expiry (for year 4) |
Feb 14 2023 | 2 years to revive unintentionally abandoned end. (for year 4) |
Feb 14 2024 | 8 years fee payment window open |
Aug 14 2024 | 6 months grace period start (w surcharge) |
Feb 14 2025 | patent expiry (for year 8) |
Feb 14 2027 | 2 years to revive unintentionally abandoned end. (for year 8) |
Feb 14 2028 | 12 years fee payment window open |
Aug 14 2028 | 6 months grace period start (w surcharge) |
Feb 14 2029 | patent expiry (for year 12) |
Feb 14 2031 | 2 years to revive unintentionally abandoned end. (for year 12) |